Read this company snapshot
Daily valuation snapshot
Atea Pharmaceuticals, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $5.15
- Market capitalization (USD)
- $413,054,199.85
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AVIR in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AVIR in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing AVIR with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $5.15 |
| Market capitalization (USD) | $413,054,199.85 |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read AVIR's valuation metrics
Company size
Atea Pharmaceuticals, Inc. Common Stock's recorded market capitalization is $413,054,199.85. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research Atea Pharmaceuticals, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about AVIR. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow AVIR's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.